Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
暂无分享，去创建一个
[1] M. Markman. Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown. , 2011, Gynecologic oncology.
[2] J. Yi,et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Eisenhauer,et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. , 2011, Gynecologic oncology.
[4] D. Cohn,et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.